Related Experiment Video
Updated: Feb 23, 2026

Development of an In Vitro Ocular Platform to Test Contact Lenses
Published on: April 6, 2016
Ophthalmic Start-Up Chief Executive Officers' Perceptions of Development Hurdles
William C Stewart1, Lindsay A Nelson, Bonnie Kruft
1PRN PharmaFarm, LLC, Cheyenne, WY, USA.
Purpose:
To identify current challenges facing ophthalmic pharmaceutical start-ups in developing new products.
Methods:
Surveys were distributed to the chief executive officer (CEO) or president of ophthalmic start-ups.
Results:
The survey attracted 24 responses from 78 surveys distributed (31%). The CEOs stated that a lack of financial capital (n = 18, 75%), FDA regulations (n = 6, 25%), and failure to meet clinical endpoints (n = 6, 25%) were their greatest development hurdles. Risk aversion to medicines in early development (n = 18, 75%), mergers and acquisitions reducing corporate choice for licensing agreements (n = 7, 29%), the emergence of large pharmaceutical-based venture capital funding groups (n = 12, 50%), and the failure of many large pharmaceutical companies to develop their own medicines (n = 10, 42%) were noted as recent prominent trends affecting fundraising.
Conclusion:
The study suggests that development funding, regulatory burden, and meeting clinical endpoints are the greatest development challenges faced by ophthalmic start-up CEOs.
Related Concept Videos
Ophthalmic Drug Delivery Systems
Glaucoma: Overview
Accessory Structures of the Eye
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Photoreceptors and Visual Pathways

